Quanterix Corp QTRX
We take great care to ensure that the data presented and summarized in this overview for Quanterix Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding QTRX
View all-
Alliancebernstein L.P. New York, NY3.27MShares$41 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.14MShares$39.3 Million0.0% of portfolio
-
Portolan Capital Management, LLC Boston, MA2.52MShares$31.6 Million2.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.2MShares$27.6 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.06MShares$25.9 Million0.01% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN1.52MShares$19 Million0.01% of portfolio
-
Granahan Investment Management, LLC Waltham, MA1.1MShares$13.8 Million0.6% of portfolio
-
Dimensional Fund Advisors LP Austin, TX888KShares$11.1 Million0.0% of portfolio
-
Easterly Investment Partners LLC876KShares$11 Million0.93% of portfolio
-
Geode Capital Management, LLC Boston, MA859KShares$10.8 Million0.0% of portfolio
Latest Institutional Activity in QTRX
Top Purchases
Top Sells
About QTRX
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Insider Transactions at QTRX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 30
2024
|
Masoud Toloue President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
368
-0.11%
|
$4,416
$12.33 P/Share
|
Nov 15
2024
|
Vandana Sriram Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
78
-0.22%
|
$858
$11.44 P/Share
|
Nov 15
2024
|
Masoud Toloue President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,120
-0.32%
|
$12,320
$11.44 P/Share
|
Oct 31
2024
|
Masoud Toloue President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
368
-0.11%
|
$4,784
$13.22 P/Share
|
Oct 15
2024
|
Vandana Sriram Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
78
-0.21%
|
$936
$12.48 P/Share
|
Oct 15
2024
|
Masoud Toloue President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,120
-0.32%
|
$13,440
$12.48 P/Share
|
Oct 02
2024
|
Ivana Magovcevic Liebisch |
BUY
Grant, award, or other acquisition
|
Direct |
12,800
+50.0%
|
-
|
Oct 01
2024
|
William P Donnelly |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+2.81%
|
$12,000
$12.5 P/Share
|
Oct 01
2024
|
Sarah E. Hlavinka |
BUY
Grant, award, or other acquisition
|
Direct |
1,200
+2.54%
|
$14,400
$12.5 P/Share
|
Oct 01
2024
|
Paul M Meister |
BUY
Grant, award, or other acquisition
|
Direct |
1,200
+0.4%
|
$14,400
$12.5 P/Share
|
Sep 30
2024
|
Masoud Toloue President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
368
-0.1%
|
$4,416
$12.5 P/Share
|
Sep 15
2024
|
Vandana Sriram Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
78
-0.21%
|
$936
$12.82 P/Share
|
Sep 15
2024
|
Masoud Toloue President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,120
-0.32%
|
$13,440
$12.82 P/Share
|
Aug 31
2024
|
Masoud Toloue President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
368
-0.1%
|
$4,784
$13.03 P/Share
|
Aug 21
2024
|
Vandana Sriram Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
927
-2.49%
|
$12,051
$13.15 P/Share
|
Aug 20
2024
|
David R Walt |
BUY
Open market or private purchase
|
Direct |
47,000
+3.06%
|
$611,000
$13.29 P/Share
|
Aug 19
2024
|
Jeffrey Thomas Elliott |
BUY
Grant, award, or other acquisition
|
Direct |
11,985
+50.0%
|
-
|
Aug 15
2024
|
Masoud Toloue President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,120
-0.32%
|
$12,320
$11.35 P/Share
|
Aug 13
2024
|
Masoud Toloue President & CEO |
BUY
Open market or private purchase
|
Direct |
19,000
+5.09%
|
$190,000
$10.9 P/Share
|
Jul 31
2024
|
Masoud Toloue President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
368
-0.11%
|
$5,152
$14.76 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 151K shares |
---|---|
Exercise of conversion of derivative security | 2K shares |
Open market or private purchase | 66K shares |
Open market or private sale | 5K shares |
---|---|
Payment of exercise price or tax liability | 27.4K shares |